---
layout: default
title: Prednisone
description: "Prednisone çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 140
evidence_level: L2
indication_count: 10
---

# Prednisone

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Prednisoneï¼šå¾é¢¨æ¿•æ€§ç–¾ç—…åˆ°åœ“ç¦¿ç—‡

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Prednisone å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Prednisone æ˜¯ä¸€ç¨®å»£æ³›ä½¿ç”¨çš„çš®è³ªé¡å›ºé†‡ï¼ŒåŸæœ¬ç”¨æ–¼é¢¨æ¿•æ€§é—œç¯€ç‚ã€æ°£å–˜ã€ä¼‘å…‹ç­‰å¤šç¨®é©æ‡‰ç—‡ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**åœ“ç¦¿ç—‡ (Alopecia Areata)** æœ‰æ•ˆï¼Œç›®å‰æœ‰ **30+ å€‹è‡¨åºŠè©¦é©—**å’Œ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é¢¨æ¿•æ€§é—œç¯€ç‚ã€æ€¥æ€§ç—…ç—‡ï¼ˆæ°£å–˜ã€ä¼‘å…‹ï¼‰ã€çš®è†šç–¾æ‚£ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | alopecia areataã€alopecia mucinosaã€telogen effluviumã€Quinquaud's folliculitis decalvansã€alopecia antibody deficiencyã€hereditary hypotrichosis with recurrent skin vesiclesã€alopecia-intellectual disability-hypergonadotropic hypogonadism syndromeã€atrichia with papular lesionsã€tenosynovitisã€granulomatous slack skin disease |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.99% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Go |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. alopecia areata</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Prednisone æ˜¯ä¸€ç¨®åˆæˆçš®è³ªé¡å›ºé†‡ï¼Œå…·æœ‰å¼·æ•ˆçš„æŠ—ç‚å’Œå…ç–«æŠ‘åˆ¶ä½œç”¨ã€‚å®ƒé€éæŠ‘åˆ¶å¤šç¨®ç‚ç—‡ä»‹è³ªå’Œå…ç–«ç´°èƒåŠŸèƒ½ä¾†ç™¼æ®ä½œç”¨ã€‚

åœ“ç¦¿ç—‡æ˜¯ä¸€ç¨®è‡ªé«”å…ç–«ç–¾ç—…ï¼Œç‰¹å¾µæ˜¯å…ç–«ç³»çµ±æ”»æ“Šæ¯›å›Šå°è‡´è„«é«®ã€‚é€™ç¨®ç–¾ç—…çš„ç—…ç†æ©Ÿè½‰æ¶‰åŠ T ç´°èƒä»‹å°çš„è‡ªé«”å…ç–«åæ‡‰ã€‚Prednisone çš„å…ç–«æŠ‘åˆ¶ä½œç”¨å¯ä»¥æŠ‘åˆ¶é€™ç¨®ç•°å¸¸çš„å…ç–«åæ‡‰ï¼Œå¾è€Œæ¸›å°‘å°æ¯›å›Šçš„æ”»æ“Šã€‚

è‡¨åºŠä¸Šï¼Œçš®è³ªé¡å›ºé†‡ï¼ˆåŒ…æ‹¬ prednisoneï¼‰å·²è¢«å»£æ³›ç”¨æ–¼æ²»ç™‚åš´é‡çš„åœ“ç¦¿ç—‡ï¼Œç‰¹åˆ¥æ˜¯èˆ‡ methotrexate ä½µç”¨æ™‚æ•ˆæœæ›´ä½³ã€‚æœ€æ–°çš„éš¨æ©Ÿå°ç…§è©¦é©—è­‰å¯¦äº†é€™ç¨®çµ„åˆç™‚æ³•çš„æœ‰æ•ˆæ€§ã€‚

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT02037191](https://clinicaltrials.gov/study/NCT02037191) | Phase 3 | å·²å®Œæˆ | 90 | Methotrexate åŠ ä½åŠ‘é‡ prednisone vs å®‰æ…°åŠ‘æ²»ç™‚åš´é‡åœ“ç¦¿ |
| [NCT02953821](https://clinicaltrials.gov/study/NCT02953821) | Phase 4 | å·²å®Œæˆ | 172 | Acthar Gel ç”¨æ–¼ç³»çµ±æ€§ç´…æ–‘ç‹¼ç˜¡æ‚£è€… |
| [NCT03616964](https://clinicaltrials.gov/study/NCT03616964) | Phase 3 | å·²å®Œæˆ | 778 | Baricitinib ç”¨æ–¼ç³»çµ±æ€§ç´…æ–‘ç‹¼ç˜¡ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [36884234](https://pubmed.ncbi.nlm.nih.gov/36884234/) | 2023 | RCT | JAMA Dermatology | Methotrexate åŠ ä½åŠ‘é‡ prednisone å°åœ“ç¦¿å…¨ç¦¿/æ™®ç¦¿æœ‰æ•ˆ |
| [26735937](https://pubmed.ncbi.nlm.nih.gov/26735937/) | 2016 | Journal Article | Dermatology | Methotrexate èˆ‡ä¸­ä½åŠ‘é‡çš®è³ªé¡å›ºé†‡ä½µç”¨æ²»ç™‚åš´é‡åœ“ç¦¿çš„å®‰å…¨æ€§å’Œç™‚æ•ˆ |
| [37467740](https://pubmed.ncbi.nlm.nih.gov/37467740/) | 2023 | Case Series | Clin Exp Dermatol | Baricitinib èˆ‡ä½åŠ‘é‡çš®è³ªé¡å›ºé†‡ä½µç”¨æ²»ç™‚éå¸¸åš´é‡çš„åœ“ç¦¿æœ‰é¡¯è‘—æ”¹å–„ |
| [1444509](https://pubmed.ncbi.nlm.nih.gov/1444509/) | 1992 | Review | Arch Dermatol | åœ“ç¦¿æ²»ç™‚çš„ç™‚æ•ˆã€å®‰å…¨æ€§å’Œæ©Ÿè½‰å›é¡§ |
| [4571041](https://pubmed.ncbi.nlm.nih.gov/4571041/) | 1973 | Journal Article | Arch Dermatol | Prednisone æ²»ç™‚åœ“ç¦¿çš„å…ç–«å­¸ç ”ç©¶ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. alopecia mucinosa</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. telogen effluvium</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. Quinquaud's folliculitis decalvans</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. alopecia antibody deficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. hereditary hypotrichosis with recurrent skin vesicles</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. atrichia with papular lesions</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.95%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. tenosynovitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.80%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. prolapse of lacrimal gland</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.66%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.66%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å¤šå¼µè¨±å¯è­‰ | ä¿ç™Œå¯§ç­‰ | éŒ åŠ‘/æ³¨å°„åŠ‘ | é¢¨æ¿•æ€§é—œç¯€ç‚ã€æ€¥æ€§ç—…ç—‡ã€çš®è†šç–¾æ‚£ç­‰ |

## å®‰å…¨æ€§è€ƒé‡

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚

é•·æœŸä½¿ç”¨çš®è³ªé¡å›ºé†‡çš„å¸¸è¦‹æ³¨æ„äº‹é …ï¼š
- éª¨è³ªç–é¬†é¢¨éšª
- è¡€ç³–å‡é«˜
- å…ç–«æŠ‘åˆ¶å°è‡´æ„ŸæŸ“é¢¨éšªå¢åŠ 
- è…ä¸Šè…ºçš®è³ªåŠŸèƒ½æŠ‘åˆ¶

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**ç”˜è‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”˜è‰å»¶é•·çš®è³ªé¡å›ºé†‡ä½œç”¨
- å»ºè­°ï¼šé¿å…é«˜åŠ‘é‡ç”˜è‰



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Latent Tuberculosis** ğŸŸ¡ Moderate
- In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid ther...

**Fibrosis** ğŸŸ¡ Moderate
- Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these p...

**Psychotic Disorders** ğŸŸ¡ Moderate
- Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.

**ç³–å°¿ç—… (Diabetes Mellitus)** ğŸŸ¡ Moderate
- Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be adminis...

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corti...

*å¦æœ‰ 17 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šGo**

**ç†ç”±ï¼š**
æœ‰é«˜å“è³ªçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆåŒ…æ‹¬ 2023 å¹´ç™¼è¡¨æ–¼ JAMA Dermatology çš„ç ”ç©¶ï¼‰è­‰å¯¦ prednisone èˆ‡ methotrexate ä½µç”¨å°åš´é‡åœ“ç¦¿æœ‰æ•ˆã€‚é€™å€‹é æ¸¬æœ‰å……åˆ†çš„è‡¨åºŠè­‰æ“šæ”¯æŒã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ ¹æ“šæ‚£è€…å€‹åˆ¥æƒ…æ³è©•ä¼°é¢¨éšªæ•ˆç›Š
- è€ƒæ…®èˆ‡ methotrexate æˆ– JAK æŠ‘åˆ¶åŠ‘ä½µç”¨
- åˆ¶å®šé•·æœŸç›£æ¸¬è¨ˆç•«ï¼ˆéª¨å¯†åº¦ã€è¡€ç³–ç­‰ï¼‰


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Vonoprazan]({{ "/drugs/vonoprazan/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Isosorbide Dinitrate]({{ "/drugs/isosorbide_dinitrate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Carboplatin]({{ "/drugs/carboplatin/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Regorafenib]({{ "/drugs/regorafenib/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Prednisoneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/prednisone/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_prednisone,
  title = {Prednisoneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/prednisone/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
